Literature DB >> 24525025

ARF tumor suppression in the nucleolus.

Leonard B Maggi1, Crystal L Winkeler1, Alexander P Miceli1, Anthony J Apicelli1, Suzanne N Brady1, Michael J Kuchenreuther1, Jason D Weber2.   

Abstract

Since its discovery close to twenty years ago, the ARF tumor suppressor has played a pivotal role in the field of cancer biology. Elucidating ARF's basal physiological function in the cell has been the focal interest of numerous laboratories throughout the world for many years. Our current understanding of ARF is constantly evolving to include novel frameworks for conceptualizing the regulation of this critical tumor suppressor. As a result of this complexity, there is great need to broaden our understanding of the intricacies governing the biology of the ARF tumor suppressor. The ARF tumor suppressor is a key sensor of signals that instruct a cell to grow and proliferate and is appropriately localized in nucleoli to limit these processes. This article is part of a Special Issue entitled: Role of the Nucleolus in Human Disease.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ARF; Cell cycle; Nucleolus; Ribosome; p53

Mesh:

Substances:

Year:  2014        PMID: 24525025     DOI: 10.1016/j.bbadis.2014.01.016

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  33 in total

1.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

2.  Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α.

Authors:  Robert D Kendig; Fumitake Kai; Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Invest       Date:  2017-04-13       Impact factor: 2.176

3.  Aberrant expression of p16INK4a in human cancers - a new biomarker?

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Rep Rev       Date:  2018-01-15

4.  A conformational switch regulates the ubiquitin ligase HUWE1.

Authors:  Bodo Sander; Wenshan Xu; Martin Eilers; Nikita Popov; Sonja Lorenz
Journal:  Elife       Date:  2017-02-14       Impact factor: 8.140

5.  Aberrant Expression of p14ARF in Human Cancers: A New Biomarker?

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Tumor Microenviron       Date:  2019-02-04

6.  mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.

Authors:  William Damsky; Goran Micevic; Katrina Meeth; Viswanathan Muthusamy; David P Curley; Manjula Santhanakrishnan; Ildiko Erdelyi; James T Platt; Laura Huang; Nicholas Theodosakis; M Raza Zaidi; Scott Tighe; Michael A Davies; David Dankort; Martin McMahon; Glenn Merlino; Nabeel Bardeesy; Marcus Bosenberg
Journal:  Cancer Cell       Date:  2015-01-12       Impact factor: 31.743

7.  Aberrant expression of cyclin D1 in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Sign Transduct Insights       Date:  2015-09-20

Review 8.  Transcription factors that interact with p53 and Mdm2.

Authors:  Kazushi Inoue; Elizabeth A Fry; Donna P Frazier
Journal:  Int J Cancer       Date:  2015-07-14       Impact factor: 7.396

9.  Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival.

Authors:  D Dayde; M Guerard; P Perron; A-S Hatat; C Barrial; B Eymin; S Gazzeri
Journal:  Oncogene       Date:  2015-12-21       Impact factor: 9.867

Review 10.  Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.

Authors:  Elizabeth A Fry; Pankaj Taneja; Kazushi Inoue
Journal:  Int J Cancer       Date:  2016-09-12       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.